Antiviral Drugs Market Outlook 2031
The global antiviral drugs market size was valued at USD 40.95 Billion in 2022 and likely reach to USD 54.37 Billion by 2031, expanding at a CAGR of 3.2% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing geriatric population and increasing demand for efficient treatment of human immunodeficiency virus (HIV) infections.
Antiviral drugs are prescription medicines (pills, liquid, inhaled powder, or intravenous solution) that combat flu viruses in your body. Antiviral drugs are not available over-the-counter. They can only be obtained with a prescription from a medical professional. Antiviral drugs are not the same as antibiotics, which are used to treat bacterial infections.
The majority of antiviral drugs now in the market are intended to treat HIV, herpes viruses, SARS-CoV-2, hepatitis B and C viruses, and influenza A and B viruses. Antivirals are being developed for various disease families, according to researchers. viruses reproduce in the host's cells, therefore it's tough to create safe and efficient antiviral drugs.
This makes it challenging to develop drug targets that will interfere with the virus without damaging the cells of the host organism. Furthermore, viral diversity is a key hindrance in the development of vaccines and antiviral drugs. Patients who are at a higher risk of developing complications, have a severe illness, or are experiencing worsening symptoms should get treatment as soon as possible.
Antiviral Drugs Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of diseases such as human immunodeficiency virus (HIV), hepatitis, and influenza are projected to drive the market growth during the forecast year.
- Increasing geriatric population worldwide is anticipated to boost the market growth during the forecast period.
- Increasing advancements in epidemiology and increased awareness of viral diseases among people around the world are the factors boosting the market growth during the forecast period.
- High cost of drug development is projected to restrict the market growth.
- Increasing preventative measures for various diseases are anticipated to impede the market growth during the forecast period.
- Increasing demand for alternative treatments such as naturopathy and homeopathy are anticipated to hamper the market growth in the forecast period.
- Increasing emphasis on R&D for the development of new treatments, medicine, and technology such as vaccines and combination therapies are expected to offer lucrative opportunities for the market players.
Scope of Antiviral Drugs Market Report
The report on the global antiviral drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Antiviral drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), Type (Branded and Generic), Application (HIV, Hepatitis, Herpes, Influenza, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.
Antiviral Drugs Market Segment Insights
Reverse transcriptase inhibitors segment is expected to account for a key share of the market
Based on drug class, the antiviral drugs market is segmented into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. The reverse transcriptase inhibitors segment is expected to account for a key share of the market during the forecast period owing to its effectiveness in preventing the viral infection or slowing it down.
Nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors are two types of reverse transcriptase inhibitors (NNRTIs). Zidovudine, Stavudine, Zalcitabine, Efavirenz, Nevirapine, Etravirine, and Didanosine are some of the drugs used to treat HIV.
Branded segment is expected to constitute a key share of the market
Based on type, the antiviral drugs market is bifurcated into branded and generic. The branded segment is expected to constitute a key share of the market during the forecast period due to it is being associated as safer and effective medication compared to generic medication.
On the other hand, the generic segment is anticipated to expand at a rapid pace during the forecast period owing to its increasing application in developing countries and expiry of patent of some branded products. Furthermore, a number of companies, including Cipla Inc., Aurobindo Pharma, and Dr. Reddy's Laboratories Ltd., focus on producing generic medications at lower prices.
Hepatitis segment is expected to represent a key share of the market
Based on application, the antiviral drugs market is segmented into HIV, hepatitis, herpes, influenza, and others. The hepatitis segment is expected to represent a key share of the market during the forecast period owing to availability of various antiviral drugs such as entecavir, tenofovir, lamivudine, telbivudine, and adefovir. Antiviral medicine demand is projected to rise as the number of cases of hepatitis increases.
On the other hand, the HIV segment is anticipated to expand at a rapid pace during the forecast period due to rising incidence of HIV and, in certain cases, the resulting development of AIDS, as well as the development of a strong pipeline of antiviral medications for HIV therapy.
Antiviral Drugs Market Regional Outlook
North America is anticipated to dominate the market
On the basis of regions, the antiviral drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to presence of key players in the region, the availability of advanced healthcare infrastructure, and increasing awareness.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing patient population, improved economic stability, and the presence of a large and established generic medication industry.
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Gilead Sciences
- F. Hoffmann-La Roche AG
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Dr. Reddy’s Laboratories Ltd.
Key players competing in the antiviral drugs market are Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. Some of the key business strategies employed by the companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
For example, in May 2020, Cipla and Gilead Sciences formed a strategic collaboration to develop and market an investigational medicine for the treatment of COVID-19 patients.
For example, in June 2019, Cidara Therapeutics Inc., a biotechnology firm focusing on developing innovative anti-infectives, released new findings from trials of CB-012, its Cloudbreak antiviral Fc-conjugate (AVC) candidate for influenza. In the forecast period, the innovative product launches from this strong pipeline are expected to boost market growth.